Opinion|Videos|December 16, 2025
Insurance Coverage and Patient Education
Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- From your experience, what has insurance coverage been like for the pharmacotherapies used to treat desmoid tumors? Why might a step through with tyrosine kinase inhibitors before nirogacestat not be beneficial for patients? How do you educate patients about desmoid tumors and are there any resources that you find useful?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Ebola Cases Top 1700 as Unpaid Health Workers Strike
2
Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers
3
FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6
4
Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD
5